» Articles » PMID: 38803939

A Combination of Chitosan Nanoparticles Loaded with Celecoxib and Kartogenin Has Anti-inflammatory and Chondroprotective Effects: Results from an Model of Osteoarthritis

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 May 28
PMID 38803939
Authors
Affiliations
Soon will be listed here.
Abstract

Loading drugs in drug delivery systems can increase their retention time and control their release within the knee cavity. Hence, we aimed to improve the therapeutic efficacy of celecoxib and kartogenin (KGN) through their loading in chitosan nanoparticles (CS NPs). Celecoxib-loaded nanoparticles (CNPs) and KGN-loaded nanoparticles (K-CS NPs) were prepared using the absorption method and covalent attachment, respectively, through an ionic gelation process. The morphology, particle size, zeta potential, polydispersity index (PDI), conjugation efficiency (CE), encapsulation efficiency (EE), the release of the drug from NPs, as well as MTT and hemolysis assays, were evaluated. Then, the IL-1β-stimulated chondrocytes were treated with CNPs and K-CS NPs, individually or in combination, to explore their potential chondroprotective and anti-inflammatory effects. CNPs and K-CS NPs showed sizes of 352.6 ± 22.5 and 232.7 ± 4.5 nm, respectively, suitable for intra-articular (IA) injection. Based on the hemolysis results, both NPs exhibited good hemocompatibility within the studied range. Results showed that treating IL-1β-pretreated chondrocytes with CNPs or K-CS NPs remarkably limited the negative effects of IL-1β, especially when both types of NPs were used together. Therefore, injecting these two NPs into the knee cavity may improve drug bioavailability, rapidly suppress inflammation and pain, and promote cartilage regeneration. Meanwhile, for the first time, the study investigated the effect of the simultaneous use of celecoxib and KGN to treat osteoarthritis (OA).

Citing Articles

Targeted delivery of chrysin and 5-fluorouracil on MDA-MB-231 cancer cells by a peptide-functionalized L-DOPA-imprinted polymer.

Yosefi S, Sirati-Sabet M, Pakdel A, Nabizadeh Z, Kokhaei P, Madanchi H Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39738832 DOI: 10.1007/s00210-024-03750-z.

References
1.
Kang M, Kim J, Im G . Thermoresponsive nanospheres with independent dual drug release profiles for the treatment of osteoarthritis. Acta Biomater. 2016; 39:65-78. DOI: 10.1016/j.actbio.2016.05.005. View

2.
Joseph J, Sangeetha D, Gomathi T . Sunitinib loaded chitosan nanoparticles formulation and its evaluation. Int J Biol Macromol. 2015; 82:952-8. DOI: 10.1016/j.ijbiomac.2015.10.079. View

3.
Rai M, Pham C . Intra-articular drug delivery systems for joint diseases. Curr Opin Pharmacol. 2018; 40:67-73. PMC: 6015522. DOI: 10.1016/j.coph.2018.03.013. View

4.
Fan W, Li J, Yuan L, Chen J, Wang Z, Wang Y . Intra-articular injection of kartogenin-conjugated polyurethane nanoparticles attenuates the progression of osteoarthritis. Drug Deliv. 2018; 25(1):1004-1012. PMC: 6058480. DOI: 10.1080/10717544.2018.1461279. View

5.
Nabizadeh Z, Nasrollahzadeh M, Shabani A, Mirmohammadkhani M, Nasrabadi D . Evaluation of the anti-inflammatory activity of fisetin-loaded nanoparticles in an in vitro model of osteoarthritis. Sci Rep. 2023; 13(1):15494. PMC: 10509168. DOI: 10.1038/s41598-023-42844-1. View